Профилактика мужского бесплодия при лечении опухолей. Проблемы и решения

Одним из основных побочных эффектов противоопухолевой терапии является мужское бесплодие. В статье рассмотрены причины, механизмы и нарушения, возникающие после лечения цитостатическими препаратами, а также способы сохранения репродуктивной функции. Представлен опыт Федерального научно-клинического центра детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева в решении данной проблемы.

мужское бесплодие, химиотерапия, криоконсервация спермы, онкофертильность, гонадотоксичность, онкология у подростков и молодых взрослых, лимфома Ходжкина, острый лимфобластный лейкоз, опухоль яичка, алкилирующие препараты, сперматогенез, цитостатики, бесплодие после химиотерапии, бесплодие у подростков, лучевая терапия

1. Hirsch M., Lunenfeld B., Modan M. et al. Spermarche the age of onset of sperm emission. J Adolesc Health Care 1985;6(1):35–9.

2. Nielsen C.T., Skakkebaek N.E., Richardson D.W. et al. Onset of the release of spermatozoa (spermarche) in boys in relation to age, testicular growth, pubic hair, and height. J Clin Endocrinol Metab 1986;62(3):532–5.

3. Nieschlag E., Behre H. Andrology. Male Reproductive Health and Dysfunction. 3 ed. Springer-Verlag Berlin Heidelberg, 2010. Pp. 16–17.

4. Zhengwei Y., McLachlan R., Bremner W., Wreford N. Quantitative (stereological) study of the normal spermatogenesis in the adult monkey (Macaca fascicularis). J Androl 1997;18(6):681–7.

5. Винокуров А.А. Лимфома Ходжкина и проблемы репродукции у мужчин. Клиническая онкогематология 2013;6(3):258–73. [Vinokurov A.A. Hodgkin’s lymphoma and male fertility disorders. Klinicheskaya onkogematologiya = Clinical oncohematology 2013;6(3):258–73. (In Russ.)].

6. Винокуров А.А., Варфоломеева С.Р., Тарусин Д.И., Моисеева Т.Н. Оценка гонадотоксичности терапии по схеме ВЕАСОРР-14 у молодых мужчин, излеченных от лимфомы Ходжкина. Клиническая онкогематология 2011;4(3):235–9. [Vinokurov A.A., Varfolomeeva S.R., Tarusin D.I., Moiseeva T.N. Assessment of gonadal toxicity of Hodgkin's lymphoma in young males treated by BEACOPP-14 protocol. Klinicheskaya onkogematologiya = Clinical oncohematology 2011;4(3):235–9. (In Russ.)].

7. Steger K., Rey R., Louis F. et al. Reversion of the differentiated phenotype and maturation block in Sertoli cells in pathological human testis. Hum Reprod 1999;14(1):136–43.

8. von Eckardstein S., Simoni M., Bergmann M. et al. Serum inhibin B in combination with serum follicle-stimulating hormone (FSH) is a more sensitive marker than serum FSH alone for impaired spermatogenesis in men, but cannot predict the presence of sperm in testicular tissue samples. J Clin Endocrinol Metab 1999;84(7):2496–501.

9. Chung K., Irani J., Knee G. et al. Sperm cryopreservation for male patients with cancer: an epidemiological analysis at the University of Pennsylvania. Eur J Obstet Gynecol Reprod Biol 2004;113 Suppl 1:S7–11.

10. Williams D., Karpman E., Sander J. et al. Pretreatment semen parameters in men with cancer. J Urol 2009;181(2):736–40.

11. Marmor D., Elefant E., Dauchez C., Roux C. Semen analysis in Hodgkin's disease before the onset of treatment. Cancer 1986;57(10):1986–7.

12. Padron O.F., Sharma R.K., Thomas A.J. Jr, Agarwal A. Effects of cancer on spermatozoa quality after cryopreservation: a 12-year experience. Fertil Steril 1997;67(2):326–31.

13. Viviani S., Ragni G., Santoro A. et al. Testicular dysfunction in Hodgkin's disease before and after treatment. Eur J Cancer 1991;27(11):1389–92.

14. Bahadur G., Ozturk O., Muneer A. et al. Semen quality before and after gonadotoxic treatment. Hum Reprod 2005;20(3):774–81.

15. Gandini L., Lombardo F., Salacone P. et al. Testicular cancer and Hodgkin's disease: evaluation of semen quality. Hum Reprod 2003;18(4):796–801.

16. Rofeim O., Gilbert B. Normal semen parameters in cancer patients presenting for cryopreservation before gonadotoxic therapy. Fertil Steril 2004;82(2):505–6.

17. Rueffer U., Breuer K., Josting A. et al. Male gonadal dysfunction in patients with Hodgkin's disease prior to treatment. Ann Oncol 2001;12(9):1307–11.

18. Buch J.P., Kolon T.F., Maulik N. et al. Cytokines stimulate lipid membrane peroxidation of human sperm. Fertil Steril 1994;62(1):186–8.

19. Dousset B., Hussenet F., Daudin M. et al. Seminal cytokine concentrations (IL-1beta, IL-2, IL-6, sR IL-2, sR IL-6), semen parameters and blood hormonal status in male infertility. Hum Reprod 1997;12(7):1476–9.

20. Fedder J., Ellerman-Eriksen S. Effect of cytokines on sperm motility and ionophorestimulated acrosome reaction. Arch Androl 1995;35(3):173–85.

21. Meistrich M.L. Male gonadal toxicity. Pediatr Blood Cancer 2009;53(2):261–6.

22. Spitz S. The histological effects of nitrogen mustards on human tumors and tissues. Cancer 1948;1(3):383–98.

23. Seshadri T., Seymour J.F., McArthur G.A. Oligospermia in a patient receiving imatinib therapy for the hypereosinophilic syndrome. N Engl J Med 2004;351(20):2134–5.

24. Mariani S., Basciani S., Fabbri A. et al. Severe oligozoospermia in a young man with chronic myeloid leukemia on long-term treatment with imatinib started before puberty. Fertil Steril 2011;95(3):1120.e15–7.

25. Trottmann M., Becker A.J., Stadler T. et al. Semen quality in men with malignant diseases before and after therapy and the role of cryopreservation. Eur Urol 2007;52(2):355–67.

26. Meistrich M.L., Vassilopoulou-Sellin R., Lipshultz L.I. Adverse effects of treatment: gonadal dysfunction. 7 ed. Philadelphia: Lippincott Williams & Wilkins, 2005.

27. Colpi G.M., Contalbi G.F., Nerva F. et al. Testicular function following chemoradiotherapy. Eur J Obstet Gynecol Reprod Biol 2004;113 Suppl 1:S2–S6.

28. Meistrich M.L., Finch M., da Cunha M.F. et al. Damaging effects of fourteen chemotherapeutic drugs on mouse testis cells. Cancer Res 1982;42(1):122–31.

29. Chatterjee R., Haines G.A., Perera D.M. et al. Testicular and sperm DNA damage after treatment with fludarabine for chronic lymphocytic leukaemia. Hum Reprod 2000;15(4):762–6.

30. Abu-Baker S.O. Gemcitabine impacts histological structure of mice testis and embryonic organs. Pak J Biol Sci 2009;12(8):607–15.

31. Savkovic N., Green S., Pecevski J., Maric N. The effect of mitomycin on the fertility and the induction of meiotic chromosome rearrangements in mice and their first generation progeny. Can J Genet Cytol 1977;19(3):387–93.

32. Heim C., Minniear K., Dann C. Imatinib has deleterious effects on differentiating spermatogonia while sparing spermatogonial stem cell self renewal. Reprod Toxicol 2011;31(4):454–63.

33. Heikens J., Behrendt H., Adriaanse R., Berghout A. Irreversible gonadal damage in male survivors of pediatric Hodgkin's disease. Cancer 1996;78(9):2020–4.

34. Shafford E.A., Kingston J.E., Malpas J.S. et al. Testicular function following the treatment of Hodgkin's disease in childhood. Br J Cancer 1993;68(6):1199–204.

35. Aubier F., Flamant F., Brauner R. et al. Male gonadal function after chemotherapy for solid tumors in childhood. J Clin Oncol 1989;7(3):304–9.

36. Ben Arush M.W., Solt I., Lightman A. et al. Male gonadal function in survivors of childhood Hodgkin and non-Hodgkin lymphoma. Pediatr Hematol Oncol 2000;17(3):239–45.

37. Dhabhar B.N., Malhotra H., Joseph R. et al. Gonadal function in prepubertal boys following treatment for Hodgkin's disease. Am J Pediatr Hematol Oncol 1993;15(3):306–10.

38. Nurmio M., Keros V., Lähteenmäki P. et al. Effect of childhood acute lymphoblastic leukemia therapy on spermatogonia populations and future fertility. J Clin Endocrinol Metab 2009;94(6):2119–22.

39. Meistrich M.L. Impact of cyclophosphamide on long-term reduction in sperm count in men treated with combination chemotherapy for Ewing and soft tissue sarcomas. Cancer 1992;70(11):2703–12.

40. Reinmuth S., Hohmann C., Rendtorff R. et al. Impact of chemotherapy and radiotherapy in childhood on fertility in adulthood: the FeCt-survey of childhood cancer survivors in Germany. J Cancer Res Clin Oncol 2013;139(12):2071–8.

41. Sherins R.J., Olweny C.L., Ziegler J.L. Gynecomastia and gonadal dysfunction in adolescent boys treated with combination chemotherapy for Hodgkin's disease. N Engl J Med 1978;299(1):12–6.

42. Green D.M., Brecher M.L., Lindsay A.N. et al. Gonadal function in pediatric patients following treatment for Hodgkin disease. Med Pediatr Oncol 1981;9(3):235–44.

43. Puscheck E., Philip P.A., Jeyendran R.S. Male fertility preservation and cancer treatment. Cancer Treat Rev 2004;30(2):173–80.

44. Kinsella T.J., Trivette G., Rowland J. et al. Long-term follow-up of testicular function following radiation therapy for early-stage Hodgkin's disease. J Clin Oncol 1989;7(6):718–24.

45. Giwercman A., von der Maase H., Berthelsen J.G. et al. Localized irradiation of testes with carcinoma in situ: effects on Leydig cell function and eradication of malignant germ cells in 20 patients. J Clin Endocrinol Metab 1991;73(3):596–603.

46. Hahn E.W., Feingold S.M., Nisce L. Aspermia and recovery of spermatogenesis in cancer patients following incidental gonadal irradiation during treatment: a progress report. Radiology 1976;119(1):223–5.

47. Socie G., Salooja N., Cohen A. et al. Nonmalignant late effects after allogeneic stem cell transplantation. Blood 2003;101(9):3373–85.

48. Howell S.J., Shalet S.M. Spermatogenesis after cancer treatment: damage and recovery. J Natl Cancer Inst Monogr 2005;(34):12–7.

49. Meistrich M.L., Shetty G. Inhibition of spermatogonial differentiation by testosterone. J Androl 2003;24(2):135–48.

50. Meistrich M.L., Shetty G. Hormonal suppression for fertility preservation in males and females. Reproduction 2008;136(6):691–701.

51. Feldschuh J., Brassel J., Durso N., Levine A. Successful sperm storage for 28 years. Fertil Steril 2005;84(4):1017.

52. Horne G., Atkinson A.D., Pease E.H. et al. Live birth with sperm cryopreserved for 21 years prior to cancer treatment: case report. Hum Reprod 2004;19(6):1448–9.

53. Clarke G.N., Liu D.Y., Baker H.W. Recovery of human sperm motility and ability to interact with the human zona pellucida after more than 28 years of storage in liquid nitrogen. Fertil Steril 2006;86(3):721–2.

54. Agarwal A., Ranganathan P., Kattal N. et al. Fertility after cancer: a prospective review of assisted reproductive outcome with banked semen specimens. Fertil Steril 2004;81(2):342–8.

55. Saito K., Suzuki K., Iwasaki A. et al. Sperm cryopreservation before cancer chemotherapy helps in the emotional battle against cancer. Cancer 2005;104(3):521–4.

56. Schover L.R., Brey K., Lichtin A. et al. Knowledge and experience regarding cancer, infertility, and sperm banking in younger male survivors. J Clin Oncol 2002;20(7):1880–9.

57. Janssens P.M., Beerendonk C.C., Blokzijl E. et al. Cryopreservation of semen of adolescents and young adult men with cancer. Ned Tijdschr Geneeskd 2004;148(40):1981–4.

58. Blatt J. Pregnancy outcome in long-term survivors of childhood cancer. Med Pediatr Oncol 1999;33(1):29–33.

59. Byrne J., Rasmussen S.A., Steinhorn S.C. et al. Genetic disease in offspring of long-term survivors of childhood and adolescent cancer. Am J Hum Genet 1998;62(1):45–52.

60. Dodds L., Marrett L.D., Tomkins D.J. et al. Case-control study of congenital anomalies in children of cancer patients. BMJ 1993;307(6897):164–8.

61. Green D.M., Whitton J.A., Stovall M. et al. Pregnancy outcome of partners of male survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. J Clin Oncol 2003;21(4):716–21.

62. Kenney L.B., Nicholson H.S., Brasseux C. et al. Birth defects in offspring of adult survivors of childhood acute lymphoblastic leukemia. A Childrens Cancer Group/ National Institutes of Health Report. Cancer 1996;78(1):169–76.

63. Meistrich M.L., Byrne J. Genetic disease in offspring of long-term survivors of childhood and adolescent cancer treated with potentially mutagenic therapies. Am J Hum Genet 2002;70(4):1069–71.

64. Senturia Y.D., Peckham C.S. Children fathered by men treated with chemotherapy for testicular cancer. Eur J Cancer 1990;26(4):429–32.

65. Signorello L.B., Mulvihill J.J., Green D.M. et al. Congenital anomalies in the children of cancer survivors: a report from the childhood cancer survivor study. J Clin Oncol 2012;30(3):239–45.

66. Папуша Л.И., Младова Е.С., Хилькевич Л.В. и др. Сохранение фертильности у пациенток, перенесших трансплантацию гемопоэтических стволовых клеток. Гематология и трансфузиология 2012;57(3):70. [Papusha L.I., Mladova E.S., Khilkevich L.V. et al. Preservation of fertility in of patients after hematopoietic stem cell transplantation. Gematologiya i transfuziologiya = Hematology and Transfusiology 2012;57(3):70. (In Russ.)].

67. Поварова А.А., Гаврилов В.М., Младова Е.С. и др. Возможности ВРТ у пациенток с онкологическими заболеваниями. Международная научно-практическая конференция «Репродуктивные технологии в онкологии – 2015». Сборник материалов конференции. С. 35. [Povarova A.A., Gavrilov V.M., Mladova E.S. et al. Features of assisted reproductive technology in patients with cancer. International scientific-practical conference ‟Reproductive Technologies in Oncology – 2015”. Conference materials. P. 35. (In Russ.)].

68. Винокуров А.А., Варфоломеева С.Р., Тарусин Д.И. и др. Фертильность подростков и молодых мужчин, излеченных от лимфомы Ходжкина. Гематология и трансфузиология 2013;58(2):11–8. [Vinokurov A.A., Varfolomeeva S.R., Tarusin D.I. et al. Fertility of adolescents and young men treated for Hodgkin’s lymphoma. Gematologiya i transfuziologiya = Hematology and Transfusiology 2013;58(2):11–8. (In Russ.)].